Tetrastarch in cardiac surgery: error, confounding and bias in a meta-analysis of randomized trials

Competing interests RJN and MMW have received previous unrestricted research grant support from Baxter, CSL Behring and Grifols. FDA Safety Communication: boxed warning on increased mortality and severe renal injury, and additional warning on risk of bleeding, for use of hydroxyethyl starch solution...

Full description

Saved in:
Bibliographic Details
Published in:Critical care (London, England) England), 2015-04, Vol.19 (1), p.187-187, Article 187
Main Authors: Navickis, Roberta J, Haynes, Gary R, Wilkes, Mahlon M
Format: Article
Language:English
Subjects:
Bias
Biological products
Blood Loss, Surgical - prevention & control
Cardiac Surgical Procedures - adverse effects
Critical care
Evidence-based medicine
Health aspects
Heart surgery
Humans
Hydroxyethyl Starch Derivatives - administration & dosage
Letter
Medical errors
Meta-analysis
Plasma Substitutes - administration & dosage
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Competing interests RJN and MMW have received previous unrestricted research grant support from Baxter, CSL Behring and Grifols. FDA Safety Communication: boxed warning on increased mortality and severe renal injury, and additional warning on risk of bleeding, for use of hydroxyethyl starch solutions in some settings (2013). www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ucm358271.htm. Perfusion. 2013;28:536-40.Google Scholar Kozek-Langenecker SA, Jungheinrich C, Sauermann W, van der Linden P. The effects of hydroxyethyl starch 130/0.4 (6%) on blood loss and use of blood products in major surgery: a pooled analysis of randomized clinical trials.
ISSN:1364-8535
1466-609X
1364-8535
1366-609X
DOI:10.1186/s13054-015-0907-8